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Introduction
Many cytokines are produced at the maternofetal inter-
face (i.e. placenta, amnion and decidua) and considered
to influence pregnancy outcomes.1–3 Chemokines con-
stitute a large family of structurally related cytokines
and modulate many functions, such as enzyme secre-
tion, cell adhesion, cytotoxicity, tumor cell growth,
degranulation, and T-cell activation.4,5
The chemokine stromal cell-derived factor-1 (SDF-
1) is expressed constitutively and ubiquitously in most
tissues. It is also known as CXC chemokine ligand-12
(CXCL-12) or pre-B-cell growth-stimulating factor.
SDF-1 is expressed in trophoblasts and decreases with
gestational age.6–8 It plays an important role in tro-
phoblast cell proliferation or differentiation through the
activation of ERK1/2 or antiapoptotic signaling path-
ways.7 The interaction between CXCR4 and SDF-1 is
involved in maternofetal immunological tolerance in all
3 trimesters of gestation and contributes to the invasion
of extravillous trophoblasts when the spiral arteries
are actively remodeling for establishment of uteropla-
cental circulation.8 Furthermore, SDF-1 is a potent
angiogenic stimulator of vascular endothelial growth
factor expression, the main effector of neovasculari-
zation and the key inducer of vascular permeability.9
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SDF-1α and pregnancy outcome
Several developmental defects, including B-cell lym-
phopoiesis, bone marrow myelopoiesis, congenital
abnormality (e.g. ventricular septal defect) and even
perinatal death, occurred in mice mutants lacking
SDF-1.6
The constituents of mid-trimester amniotic fluid
may reflect changes occurring in the maternofetal
interface.2 However, it is currently not known what
variables affect SDF-1 levels or whether amniotic fluid
SDF-1 levels correlate with pregnancy outcomes.
Two spliced forms of SDF-1 (SDF-1α and SDF-
1β) have been identified, both of which have identical
amino acid sequences except for the presence of 4 addi-
tional amino acids at the carboxyl terminus of SDF-
1β.10 The significance of the existence of the 2 spliced
forms of SDF-1 is unclear. The different sensitivities
of SDF-1α and SDF-1β to proteolytic processing
provide a mechanism for chemokine functional regu-
lation and reveal a functional difference between the
2 spliced forms. In this prospective study, we measured
the concentration of SDF-1α in second trimester amni-
otic fluid samples and correlated this with pregnancy
outcomes.
Methods
Patients
Mid-trimester amniotic fluid samples were obtained
from pregnant women undergoing genetic amnio-
centesis at Taichung Veterans General Hospital from
2006 to 2008. All samples were collected from healthy
women with a singleton pregnancy. The main indica-
tions for amniocentesis included: advanced maternal
age, abnormal maternal serum screening result, and
high parental anxiety levels. The pregnant women had
no precedent risk factors for a high-risk pregnancy,
such as a pre-existing medical or surgical illness, or
obstetrics-related conditions. These pregnant women
continued with regular antenatal visits. Fetal aneu-
ploidies or major anomalies were excluded from the
analysis. The clinical characteristics were recorded for
further analysis. Pre-eclampsia was defined as blood
pressure ≥ 140/90 mmHg after 20 weeks of gestation
and proteinuria ≥ 300 mg/24 hours or ≥ 1 + dipstick
(30 mg/dL).11 According to the 100-g oral glucose
tolerance test, diagnosis of gestational diabetes requires
≥ 2 abnormal values.12 Abnormal placentation in-
cluded placenta previa with or without placenta acc-
reta (abnormal trophoblast invasion into the uterine
myometrium). Small for gestational age describes a
neonate whose birth weight is at least 2 standard
deviations below the mean (≤ –2 SD) for the infant’s
gestational age.13 This research protocol was approved
by the Medical Research Council (Institutional Review
Board) of Taichung Veterans General Hospital (941003/
C05168), and informed consent was obtained from
all patients.
Enzyme-linked immunosorbent assay (ELISA)
Amniotic fluid specimens were centrifuged at 1,000g
for 10 minutes. The supernatants were collected and
kept at –80°C until required. SDF-1α concentrations
were determined with RayBio® Human SDF-1α ELISA
kit (RayBiotech Inc., Norcross, GA, USA) according
to the manufacturer’s instructions. Briefly, supernatants
of amniotic fluid and standards were pipetted into
wells precoated with an antibody specific for human
SDF-1α. After incubation overnight at 4°C and a
total of 4 washes with wash buffer, biotinylated anti-
human SDF-1α antibody, horseradish peroxidase-
conjugated streptavidin and tetramethylbenzidine
substrate solution were added sequentially into the
wells. After the addition of stop solution, the optical
density was determined using a microplate reader set
to 450 nm. The intraassay and interassay coefficients
of variation were less than 10% and 12%, respectively.
Curve-fitting and dose interpolation were performed
by software provided with the optical density reader.
Samples were measured in triplicate. To exclude the
effects of storage time on SDF-1α levels, the speci-
mens from 2 different storage times for each of the 
10 amniotic fluid samples were chosen and compared.
Statistical analysis
Statistical analysis was performed using SPSS version
11.0 (SPSS Inc., Chicago, IL, USA) and MedCalc
version 9.3 (MedCalc Software, Mariakerke, Belgium).
A receiver operating characteristic curve was constructed
to establish the cutoff values of SDF-1α with differ-
ent variables. The area under the receiver operating
characteristic curve and 95% confidence interval of
the curve were analyzed. Predictive cutoffs were then
determined. Based on the established cutoff point,
continuous (maternal age at sampling, body mass index
at sampling, gestational weeks at sampling, gestational
weeks at delivery, and birth weight) and category
variables (parity, preterm birth rate, delivery mode,
birth weight category, Apgar scores at 1 minute and 
5 minutes, and gender) were further analyzed using
Fisher’s exact test, Mann-Whitney U test, Pearson’s
χ2 test, and Yates’ correction of contingency as appro-
priate. Selected maternal follow-up outcomes including
gestational diabetes, pre-eclampsia, and abnormal pla-
centation were also investigated. Pearson’s correlation
coefficient was used to correlate SDF-1α concentration
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and continuous variables. Multivariate regression analy-
ses with backward selection were then conducted. For
all analyses, p < 0.05 was considered significant. The
nonparametric Wilcoxon signed-rank test for 2 related
samples was used for analyzing the effect of storage
time on SDF-1α levels.
Results
A total of 210 mid-trimester amniotic fluid samples
were collected. The storage time, which ranged from
2 to 4 months, did not affect SDF-1α concentration
(p > 0.05). The maternal and neonatal characteristics
are shown in Table 1. We identified a cutoff value 
of SDF-1α (6.42 pg/mL), which would provide an
optimal sensitivity and specificity in predicting Apgar
score at 1 minute (< 7 vs. ≥ 7) (p = 0.046). There was a
trend toward higher preterm birth rate (p = 0.048),
lower birth weight (p = 0.0396), higher small for ges-
tational age rate (p = 0.004) and lower 1-minute and
5-minute Apgar scores (p = 0.0004 and 0.039, respec-
tively) when the SDF-1α level was ≥ 6.42 pg/mL.
As shown in Table 2, the overall p value between nor-
mal (158 cases) and selected pregnancy outcomes (7
gestational diabetes, 13 pre-eclampsia, and 5 abnormal
Table 1. Maternal and neonatal characteristics*
Characteristics
Mean ± SD or n (%)
Overall p
< 6.42 (n = 180) ≥ 6.42 (n = 30)
Maternal age at sampling (yr) 34.50 ± 4.26 33.83 ± 4.23 0.171†
Parity (% nulliparity) 66 (36.7) 13 (43.3) 0.621‡
BMI at sampling (kg/m2) 27.29 ± 3.66 26.47 ± 4.22 0.336†
Gestational weeks at sampling 17.08 ± 1.98 16.77 ± 1.14 0.656†
Gestational weeks at delivery 38.42 ± 2.72 36.83 ± 4.65 0.128†
Preterm birth rate (< 37 wk) 22 (12.2) 8 (26.7) 0.048§
Delivery mode (% vaginal delivery) 99 (55.0) 16 (53.3) 1.000‡
Birth weight (g) 3,094.53 ± 599.56 2,643.80 ± 1,001.58 0.0396†
Birth weight category (% SGA) 2 (1.1) 4 (13.8) 0.004§
Apgar score at 1 min 0.0004§
< 7 11 (6.1) 9 (30.0)
≥ 7 169 (93.9) 21 (70.0)
Apgar score at 5 min 0.039§
< 7 6 (3.3) 4 (13.3)
≥ 7 174 (96.7) 26 (86.7)
Gender of neonate (% male) 96 (53.3) 17 (56.7) 0.888‡
*The cutoff point (6.42 pg/mL) was established by receiver operating characteristic curve analysis; †Mann-Whitney U test; ‡Yates’ correction of contingency;
§Fisher’s exact test. SD = standard deviation; BMI = body mass index; SGA = small for gestational age.
Table 2. Selected maternal follow-up outcomes*
Outcome
n (%) Overall Pair comparison
< 6.42 (n = 158) ≥ 6.42 (n = 25) p value
† p value‡
0.233
Normal§ 139 (88.0) 19 (76.0) –
GDM 6 (3.8) 1 (4.0) 1.000
Pre-eclampsia 10 (6.3) 3 (12.0) 0.379
Abnormal placentation 3 (1.9) 2 (8.0) 0.125
*The cutoff point (6.42 pg/mL) was established by receiver operating characteristic curve analysis; †Pearson’s c2 test; ‡Fisher’s exact test; §normal is the base
set; included placenta previa with or without placenta accreta. GDM = gestational diabetes mellitus.
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placentation) was not significant (p = 0.233). The pair
comparison between normal and each of the selected
pregnancy outcomes also showed no significant dif-
ference (p > 0.05).
In Table 3, the correlation of mid-trimester amni-
otic SDF-1α levels to continuous variables found that
gestational age at delivery (r = –0.151, p = 0.028) and
birth weight (r = –0.194, p = 0.0048) were statistically
significant. This is consistent with the findings shown
in Table 1. According to multivariate regression analy-
sis on mid-trimester SDF-1α levels (Table 4), mater-
nal age at sampling (regression coefficient = –0.163,
p = 0.0057) and Apgar score at 1 minute (< 7 vs. ≥ 7,
regression coefficient = 2.028, p = 0.019) were signifi-
cant variables.
Discussion
It has been suggested that SDF-1 is expressed in tropho-
blasts and decreases with gestation time. It is involved in
maternal-fetal immunological tolerance in all trimesters
of pregnancy.8 SDF-1 is one of many factors involved
in the process of trophoblast invasion, which is respon-
sible for the establishment of uteroplacental blood flow
after remodeling of the spiral arteries. It also suppresses
apoptosis and enhances trophoblast cell survival during
pregnancy.14 Adjacent structures such as the placenta,
fetal membranes and the decidua are thought to partic-
ipate in the formation of amniotic fluid.2 Therefore,
we chose amniotic fluid as a safely available sample
from which to measure the SDF-1α levels in order to
obtain information on what is occurring at the mater-
nofetal interface. This may be predictive of pregnancy
outcomes.
The present study demonstrated that a higher SDF-
1α level was predictive for a higher preterm birth rate,
lower birth weight, higher small for gestational age
rate, and lower Apgar scores. Our data suggested that
increased SDF-1α levels in mid-trimester amniotic
fluid are related to the occurrence of adverse pregnancy
outcomes and possibly reflect the events taking place
at the maternofetal interface in response to changes in
uteroplacental function, uterine arterial remodeling,
and circulating levels of other cytokines in early ges-
tation. It is possible that a regulated suppression of
the apoptotic cascade through a higher SDF-1α level
is required for the maintenance of improved uteropla-
cental functions when the pregnancy has been primarily
associated with functional impairment of trophoblast
attachment, migration, or invasiveness affected by differ-
ent intra- and extracellular effector molecules.
A strong predisposing factor for pre-eclampsia is
defective trophoblast invasion.15,16 In contrast, pla-
centa previa increta/percreta, a severe form of abnor-
mal placentation, is associated with excessive trophoblast
invasion into the uterine myometrium during place-
ntal development.17 Although SDF-1α is related to
trophoblast invasion and survival, we did not find any
significant differences in the concentrations of SDF-
1α between normal pregnancies and those with sub-
sequent pre-eclampsia or abnormal placentation. In
the pre-eclampsia group (13 patients), the highest mid-
trimester amniotic fluid SDF-1α level (15.84 pg/mL)
came from a patient with HELLP syndrome (hemolytic
anemia, elevated liver enzymes, and low platelets).
Furthermore, in the abnormal placentation group (5
patients), the highest SDF-1α level (8.08 pg/mL)
occurred in a patient with placenta increta (excessive
trophoblast invasion of the uterine myometrium with
Table 3. Correlation of mid-trimester amniotic stromal cell-derived
factor-1 (SDF-1α) levels (pg/mL) with continuous variables
Pearson’s 
Variable correlation p
coefficient
Maternal age at sampling –0.122 0.079
BMI at sampling –0.058 0.407
Gestational weeks at sampling –0.088 0.202
Gestational weeks at delivery –0.151 0.028
Birth weight –0.194 0.0048
BMI = body mass index.
Table 4. Multivariate regression analysis on mid-trimester stromal cell-derived factor-1 (SDF-1α) levels (pg/mL)
Variable Regression coefficient β Standard error t p
Constant 13.170 – 3.446 3.822 0.0002
Gestational weeks at sampling* −0.256 −0.141 0.131 −1.956 0.0519
Maternal age at sampling* −0.163 −0.202 0.058 −2.796 0.0057
Apgar score at 1 min† 2.028 0.163 0.857 2.365 0.019
Note. This model includes the following variables: maternal age at sampling, parity, body mass index, gestational weeks at sampling, birth weight, birth weight
category, and Apgar score at 1 minute and 5 minutes. All variables with a p value ≤ 0.10 are shown. Backward regression method was used. The model’s entire
p = 0.006 (analysis of variance F = 4.297). *Continuous; †< 7 compared with ≥ 7 (reference).
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abnormal neovascularization). More patients should
be studied to determine the role of SDF-1α in the
development of specific pregnancy disorders.
In addition to the 210 cases in the present study, 
9 cases with chromosomal abnormalities were diagnosed
(3 numerical, 3 structural and 3 sex chromosomal dis-
orders). The SDF-1α levels of these cases were also
measured during the study period. The relationship
between the development of a chromosomal disorder
with the SDF-1α level in the mid-trimester amniotic
fluid was not significant (p > 0.05). However, 2 cases
with trisomy 21 among the 9 cases with chromosomal
disorders had the highest SDF-1α levels in the group
(7.73 pg/mL and 8.99 pg/mL, respectively). One case
(46,XY) with cystic hygroma diagnosed at 20 weeks
of gestation had a SDF-1α level of 24.65 pg/mL at
15 weeks of gestation. It would be worthwhile study-
ing the difference in SDF-1α between normal and
abnormal pregnancies further.
In conclusion, increased SDF-1α levels in mid-
trimester amniotic fluid suggest a possible role for pre-
dicting pregnant women at risk of a higher preterm
birth rate, lower birth weight, and lower Apgar scores.
However, the clinical usefulness of this test for patho-
logical pregnancies needs to be investigated further.
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